Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients
A two-fold prolongation of activated partial thromboplastin time (APTT) is established as therapeutic range for therapy with unfractionated heparin, hirudin and argatroban. The international normalized ratio (INR) of 2 to 3 is required to maintain anticoagulation in the therapeutic range of vitamin...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 2016
|
| In: |
Thrombosis research
Year: 2016, Jahrgang: 140 |
| ISSN: | 1879-2472 |
| DOI: | 10.1016/S0049-3848(16)30117-7 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/S0049-3848(16)30117-7 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0049384816301177 
|
| Verfasserangaben: | Job Harenberg |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1672139260 | ||
| 003 | DE-627 | ||
| 005 | 20220816214239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190826s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0049-3848(16)30117-7 |2 doi | |
| 035 | |a (DE-627)1672139260 | ||
| 035 | |a (DE-599)KXP1672139260 | ||
| 035 | |a (OCoLC)1341238513 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Harenberg, Job |d 1950- |e VerfasserIn |0 (DE-588)108825507 |0 (DE-627)655891498 |0 (DE-576)339563745 |4 aut | |
| 245 | 1 | 0 | |a Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients |c Job Harenberg |
| 264 | 1 | |c April 2016 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.08.2019 | ||
| 520 | |a A two-fold prolongation of activated partial thromboplastin time (APTT) is established as therapeutic range for therapy with unfractionated heparin, hirudin and argatroban. The international normalized ratio (INR) of 2 to 3 is required to maintain anticoagulation in the therapeutic range of vitamin K antagonists. The therapeutic range of anti-factor Xa activity during therapy with low-molecular weight heparins and danaparoid are less well and of direct oral anticoagulants (DOAC) poorly defined. The relation of aPTT and INR values to thrombotic and bleeding events are well established despite a large variation of values in affected patients. The relation of coagulation values of the other anticoagulants to clinical events is open. The value of determination in cancer patients is higher because of the increased risk for thrombotic and bleeding events of this patient group. Several activities are currently undertaken to certify methods for in vitro diagnostic testing for DAOCs. | ||
| 650 | 4 | |a Anticoagulants | |
| 650 | 4 | |a Apixaban | |
| 650 | 4 | |a Dabigatran | |
| 650 | 4 | |a Laboratory methods | |
| 650 | 4 | |a Rivaroxaban | |
| 650 | 4 | |a Warfarin | |
| 773 | 0 | 8 | |i Enthalten in |t Thrombosis research |d Amsterdam [u.a.] : Elsevier Science, 1972 |g 140(2016, Supplement 1) Seiten S165-S167 |h Online-Ressource |w (DE-627)30671082X |w (DE-600)1500780-7 |w (DE-576)098253263 |x 1879-2472 |7 nnas |a Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients |
| 773 | 1 | 8 | |g volume:140 |g year:2016 |g supplement:1 |g extent:3 |a Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S0049-3848(16)30117-7 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0049384816301177 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190826 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 108825507 |a Harenberg, Job |m 108825507:Harenberg, Job |d 60000 |e 60000PH108825507 |k 0/60000/ |p 1 |x j |y j | ||
| 999 | |a KXP-PPN1672139260 |e 3508958396 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"April 2016","dateIssuedKey":"2016"}],"id":{"eki":["1672139260"],"doi":["10.1016/S0049-3848(16)30117-7"]},"name":{"displayForm":["Job Harenberg"]},"physDesc":[{"extent":"3 S."}],"relHost":[{"pubHistory":["1.1972 -"],"part":{"year":"2016","text":"140(2016, Supplement 1) Seiten S165-S167","volume":"140","extent":"3"},"note":["Gesehen am 15.11.23"],"disp":"Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patientsThrombosis research","type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"30671082X","language":["eng"],"title":[{"subtitle":"vascular obstruction, hemorrhage and hemostasis","title":"Thrombosis research","title_sort":"Thrombosis research"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1972-","dateIssuedKey":"1972","publisher":"Elsevier Science","publisherPlace":"Amsterdam [u.a.]"}],"id":{"issn":["1879-2472"],"zdb":["1500780-7"],"eki":["30671082X"]}}],"title":[{"title":"Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients","title_sort":"Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients"}],"person":[{"given":"Job","family":"Harenberg","role":"aut","display":"Harenberg, Job","roleDisplay":"VerfasserIn"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 26.08.2019"],"language":["eng"],"recId":"1672139260"} | ||
| SRT | |a HARENBERGJLABORATORY2016 | ||